Skip to main content

Table 1 Review of literature with comparison of previous and present studies of OnabotA-injections in PD

From: Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease

Reference Sample size Age [yrs] Gender Disease duration [yrs] Dosage/sites Injection localisation Outcome measure Result Follow-up
Giannantoni et al. [15] 4 72–83 F (4) 4–12 200 IU/20 Intradetrusor incl. Trigone UDI bladder diary Pressure flow QoL Urinary frequency (day-/nighttime) decreased No urgency/urge incontinence ICIQ/UDI improved PVR increased no side effects 1/3 months 5 months Telephone interview
Giannantoni et al. [22] 8 66 ± 3 F (7) M (1) N/A 100 IU/10 Intradetrusor UDI bladder diary Urinary frequency (day-/nighttime) decreased ICIQ/UDI improved PVR increased PVR 250 mL -- > ISC in 2 female patients 1/3/6 months
Anderson et al. [14] 20 71.5 F (8) M (12) 10.6 100 IU/10–20 Intradetrusor incl. Trigone UDI bladder diary Pressure flow QoL (KHQ) Urinary frequency (day-/nighttime) decreased PVR increased AUA Symptom score decreased 6 months
Kulaksizoglu et al. [21] 16 67.2 ± 5.1 F (10) M (6) 6 500 IU/30 Dysport® Intradetrusor bladder diary QoL (SEAPI) Urinary frequency (day-/nighttime) decreased No incontinence in 27 % patients ICIQ VAS scale caregiver PVR increased no side effects 1 week 3/6/9/12 months
Present study 10 67.9 ± 5.3 F (4) M (6) 9.2 ± 8.2 200 IU/20 Intradetrusor incl. Trigone UDI bladder diary QoL (ICIQ) Urinary frequency (day-/nighttime) decreased UDI improved QoL (ICIQ) improved PVR increased no side effects 4 months
  1. yrs years, F female, M male, IU international units, ICIQ international consultation on incontinence questionnaire, UDI urodynamic investigation, PVR post void residual, ISC internittend self-catheterization, AUA American urological association, VAS visual analog scale, QoL quality of life, incl. inclusive